Compounding Pharmacy and Telehealth: What Providers Need to Know About the DEA Rules
DEA’s compounding rules aren’t really about whether a pharmacy can compound a controlled substance. They’re about who’s doing it, how much, and whether the volume crosses from individualized dispensing into something that looks more like unregistered manufacturing.
What Does DEA Actually Allow a Pharmacy to Compound?
Under DEA’s compounding policy, a registered pharmacy can compound a controlled substance when filling a valid, patient-specific prescription in the regular course of dispensing. That’s covered under the pharmacy’s existing DEA registration, no extra paperwork needed.
The line gets crossed when compounding happens in anticipation of prescriptions rather than in response to one, or when a pharmacy is supplying other pharmacies or practitioners rather than dispensing directly to a patient. At that point, DEA treats it as manufacturing, which requires a completely separate registration.
Why Does This Matter More for Telehealth-Affiliated Pharmacies?
Because telehealth platforms tend to route most or all of their prescriptions through one or a small number of fulfillment pharmacies. That concentration creates volume, and volume is exactly what blurs the line between dispensing and manufacturing.
There’s a separate but related volume question too: DEA’s “Five Percent Rule” lets a retail pharmacy distribute up to 5% of its total controlled substance dosage units annually without needing a distributor registration. Beyond that threshold, a separate registration kicks in. If your fulfillment pharmacy is moving high volumes for a telehealth platform, that’s worth checking even apart from the compounding question.
Does This Apply Differently to Schedule II Drugs Like Stimulants?
Yes, and this is where the Adderall shortage created real compliance headaches. DEA’s compounding allowance for Schedule II substances, like the amphetamine salts used in ADHD treatment, is narrower than for other schedules. Compounding has to tie to a specific prescription already in hand. There’s no room to compound ahead of anticipated demand, even during a documented shortage.
Telehealth ADHD platforms that scaled compounded stimulant alternatives during the shortage ran straight into this restriction. The shortage explained the demand. It didn’t change the rule about compounding in advance of it.
What About Ketamine and Other Schedule III Telehealth Treatments?
At-home ketamine therapy for depression or PTSD, delivered via telehealth, typically relies on a compounding pharmacy producing troches or lozenges that get shipped to the patient. Ketamine is Schedule III, which falls under the more permissive general compounding language than Schedule II does.
That said, DEA has flagged the broader pattern, telehealth platforms routing prescriptions through a single compounding pharmacy at scale, as a diversion-risk profile worth watching, separate from the compounding-itself question. Worth being clear on one more point: this is an entirely different regulatory lane from the compounded GLP-1 disputes you may have heard about. Semaglutide and tirzepatide aren’t controlled substances, so DEA has no jurisdiction there at all. Those fights are between manufacturers and compounders under FDA’s framework, not DEA’s.
What Should Telehealth Providers and Their Pharmacy Partners Do?
- Confirm your fulfillment pharmacy is compounding against individual, prescription-specific orders, not stockpiling ahead of anticipated demand.
- If you rely on a single compounding pharmacy at high volume, check whether their dispensing pattern could approach the Five Percent Rule threshold and require a distributor registration.
- For Schedule II compounds specifically, confirm each batch ties to a prescription already received, not a forecast of expected prescriptions.
- Don’t conflate GLP-1 compounding disputes with controlled-substance compounding rules. They sit under completely different agencies and frameworks.
- Consult your compliance counsel.
Source
FDA, 2025: Compounding and FDA — Questions and Answers
This post is for educational purposes only and does not constitute legal or compliance advice. Consult a qualified attorney or compliance professional before acting on this information.
